Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20998649 | 0.79 | — | — | |
| SCHEMBL12724346 | 0.78 | MAPK13 (0.33) | ALDH1A1LMNA | |
| SCHEMBL13177050 | 0.75 | GDA (0.32) | GDASRCCYP3A4PMP22ALDH1A1 | |
| SCHEMBL21030280 | 0.69 | GDA (0.33) | GDASRCCYP3A4PMP22ALDH1A1 | |
| SCHEMBL20998703 | 0.64 | — | — | |
| SCHEMBL23731210 | 0.62 | GDA (0.30) | GDASRC | |
| SCHEMBL19090582 | 0.60 | — | — | |
| SCHEMBL20011291 | 0.60 | GDA (0.31) | GDACYP3A4PMP22ALDH1A1LMNA | |
| SCHEMBL6860784 | 0.60 | GDA (0.31) | GDACYP3A4PMP22ALDH1A1LMNA | |
| SCHEMBL24079417 | 0.59 | GDA (0.30) | GDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265626-B1 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | LCB PHARMA INC (CA) | 2019-05-15 | — | — | EP | disclosed |
| US-9732110-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9675632-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160159843-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160058783-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-9085599-B2 | 2′allene-substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8846636-B2 | Nucleoside analogues with quaternary carbon stereogenic centers and methods of use | LCB PHARMA INC. (CA) | 2014-09-30 | — | — | US | disclosed |
| US-20120237480-A1 | 2'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-09-20 | — | — | US | disclosed |
| US-8163707-B2 | 4′-allene-substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100074889-A1 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159843-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | PCNA, ENTPD5, NME2 | GDA 198/4885SRC 2002/4885CYP3A4 2772/4885 |
| US-20120237480-A1 | 2'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | NME2, HAVCR2, ENTPD5 | GDA 161/4885SRC 4037/4885CYP3A4 1205/4885 |
| US-20100074889-A1 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | CCNI, CCNA1, CDK1 | GDA 554/4885SRC 1729/4885CYP3A4 403/4885 |
| US-20160058783-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | PCNA, ENTPD5, NME2 | GDA 198/4885SRC 2002/4885CYP3A4 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.